ArticleDigestive diseases and sciences2026
Role of AQP1 in the Ameliorating Effect of Electroacupuncture in a Rodent Model of Visceral Hypersensitivity.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- On the Mechanistic Role of AQP1 in Electroacupuncture-Mediated Improvement of Visceral Hypersensitivity.Digestive diseases and sciences · 2026Article
- Response to "On the Mechanistic Role of AQP1 in Electroacupuncture-Mediated Improvement of Visceral Hypersensitivity".Digestive diseases and sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAquaporins 1 (AQP1), the first water channel protein, is involved in central and peripheral nociception. However, it remains unclear whether AQP1 contributes to visceral hypersensitivity. We hypothesize that AQP1 contributes to acetic acid-induced visceral hypersensitivity in a rat model of irritable bowel syndrome (IBS) and that electroacupuncture (EA) improves visceral hypersensitivity by down-regulating the expression of AQP1 in enteric glial cells (EGCs) and dorsal root ganglion (DRG).
methodsAnimal experiments were conducted in two batches, the first batch consisted of 32 male Sprague-Dawley rats were randomly divided into four groups: control, model, EA, and sham EA. The IBS model was established by acetic acid enema in neonatal rats, and the experiments were conducted after they reached adulthood. The rats were placed with one pair of electrodes at the external oblique muscles for electromyogram (EMG) recording, and visceral sensitivity during colorectal distension (CRD) with 0.4, 0.8, and 1.2 ml of injected water was assessed. The rats' bilateral Zusanli acupoints (ST-36) were used for electroacupuncture (EA). The expressions of AQP1, EGC activation markers (S100β), and NF-κB in colonic tissues and DRG were assessed by real-time PCR, Western blot, and immunofluorescence. ELISA was used to measure the amounts of IL-1β and IL-18 in the serum. In the second batch, twenty-four rats were randomly divided into three groups: control, model, NF-κB inhibitor group (PDTC group), and similarly performed VMR, AQP1 expression assays to verify the regulatory effect of NF-κB pathway on AQP1 and EGC in vivo. Meanwhile, enteric glial cells were cultured in vitro and activated with lipopolysaccharide (LPS), NF-κB inhibitor intervention; real-time PCR and Western blot were performed to detect the expression of AQP1 and S100β to confirm the effect of NF-κB pathway on AQP1 in vitro.
resultsAt 0.8 ml and 1.2 ml expansion volumes, visceral sensitivity was significantly increased in the model group, and electroacupuncture reversed this change, with no such effect in the sham electroacupuncture (sham EA) group. In the colon, AQP1 colocalizes with S100β, and compared with the control group, the protein expression of AQP1, phosphorylated nuclear factor kappa B p65 (p-p65), S100β in the colon, and the serum levels of IL-1β and IL-18 were markedly increased of the model group; electroacupuncture decreased VMR score, the serum levels of IL-1β and IL-18, and downregulated the protein expression of AQP1, p-p65, S100β, whereas sham EA group showed no such changes. In the dorsal root ganglion (T13-L2), AQP1 was mainly expressed in neurons with a smaller diameter, and the changing trend of AQP1, p-p65 in each group was consistent with that in the colon. In addition, AQP1 expression was downregulated in EGC after NF-κB inhibitor (PDTC) treatment both in vivo and in vitro.
conclusionEA ameliorates visceral hypersensitivity in a rodent model of IBS by down-regulating AQP1 expression and inhibiting the NF-κB pathway and may have a therapeutic potential in the treatment of visceral hypersensitivity.
Indexed as
Identifiers
40762756What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.